

Welcome







Medicine Quality & Public Health Course at Boston University School of Public Health Boston + July 10-14, 2017

Medicines Regulation in Low and Middle Income Countries (LMICs)

Souly Phanouvong, BPharm, PharmD., 2PhDs. Promoting the Quality of Medicines Program Global Public Health Programs | United States Pharmacopeial Convention







- 1. Medicines quality why it is important?
- 2. Medicines regulation development and evolution
- 3. Medicines regulation implementing agencies, key regulatory functions and challenges
- 4. What factors contribute to effective medicines regulation?



Provide participants some key information to increase understanding of Medicines Regulation and its evolution, and challenges in its implementation



The suitability of a medicinal product for its intended use is defined by:

- Its efficacy weighed against safety (health risks) according to a label claim or as promoted
- Its conformity to specifications regarding identity, strength, purity, and other characteristics, e.g., hardness, disintegration, dissolution property, impurity, sterility, etc.
- Medicine = API(s) + excipient(s) + information + package + labels



How can a medicine's quality be established, assessed/evaluated?

MEDICINES SITUATION IN MOST LMICS

- 1. Most countries have an MRA and formal requirements for registering medicines, but differ substantially in their capacity and resources, and in their overall effectiveness.
- 2. The quality of medicines varies greatly in these countries in manufacturing and in the distribution system.
- 3. Regulatory gaps are common.
- 4. Three types of common imbalance have been identified in regulatory practice:
 - Over-concentration on pre-market post-market monitoring and regulating the distribution system
 - More attention given to inspection of manufacturing practice than of distribution channels.
- 5. Whilst regional and international harmonization of regulatory guidelines and practices are desirable, the current process allows inadequate expression of the needs.


MEDICINES REGULATION - BRIEF HISTORY

- BC 120 Mithridates VI Mithridatium contained 41 individual components for almost all diseases. In 1540 manufactured Mithridatium was subjected to supervision under Apothecaries Wares, Drugs and Stuffs Act
- 1581 1st Spanish Pharmacopoeia
- 1618 The London Pharmacopoeia
- After WWII modern medicines regulations started knowledge base
- 1937 DEG poisoning in USA FDCA
- 1958-1960 Thalidomide tragedy
- 1962 the GMP compliance regulation

MAIN REASONS FOR REGULATING MEDICINES

The focus in Medicines Regulation and Public Health is on establishing and strengthening MRAs to develop norms and standards to ensure the quality, safety and efficacy of all pharmaceutical products and to put in place necessary infrastructures and procedures for QA/QC systems, as well make objective information available to the public





Promoting the Quality of Medicines ©2016. ALL RIGHTS RESERVED



- 1. There is an 'information asymmetry' between those who manufacture/sell, prescribe/dispense medicines and patients/consumers, who are not equipped to make independent assessments of the quality, safety or efficacy of their medicines
- 2. In complex global pharmaceutical supply chains, there are many opportunities for unsafe products to be introduced before reaching the consumer




Promoting the Quality of Medicines ©2016. ALL RIGHTS RESERVED.

MEDICINES REGULATION – PURPOSE


Medicines regulation incorporates several mutually reinforcing activities, all aim at promoting and protecting public health.

- Timely access to safe, efficacious and quality health products
- Good regulation can offer competitive economic advantage
- Supports development of dynamic, innovative and sustainable healthcare systems
- Being too cautious can cause negative consequences






DEVELOPMENT PATHS OF MEDICINES LAWS AND REGULATIONS





DEVELOPMENT PATHS OF MEDICINES LAWS AND REGULATIONS



Consequently, ML&Rs need to be updated to keep pace with changes and new challenges in their environment

Promoting the Quality of Medicines | ©2016. ALL RIGHTS RESERVED.

DEVELOPMENT PATHS OF MEDICINES LAWS AND REGULATIONS




Consequently, ML&Rs need to be updated to keep pace with changes and new challenges in their environment

Promoting the Quality of Medicines | ©2016. ALL RIGHTS RESERVED




The Food Safety Modernization Act expands the FDA's powers with the goal of building a food safety system based on prevention.

REGULATORY FRAMEWORK



REGULATORY FRAMEWORK





ML and Rs need to be evolved and updated to keep pace with changes and new challenges in their environment

In response to complexity and sophistication of pharmaceutica sector and perceived needs of society

While MLs provide the basis for MRs, regulatory tools such as norms, standards and guidelines equip MRAs with the practical means of implementing those laws.

The absence of regulatory tools may lead to variations in the implementation of the law, or even lead to questions about the transparency of law enforcement and practices of the MRAs

Medicines law, MRA, evaluation board, QC lab, drug information center, PV center, etc. a result of crises / deaths


f lic demand p enactment of effective medicine law or adoption of more restrictive legislation to provide stronger safeguards for the public







Promoting the Quality of Medicines ©2016. ALL RIGHTS RESERVED.



Duke-NUS Centre of Regulatory Excellence

Source: John Lim, 2016. Overview of Centre of Regulatory Excellence. Presentation presented at United States Pharmacopeial Convention.



INCREASE RELEVANCE IN REGULATION

- 1. Continuing systematic review of existing rules and regulations to ensure relevance and effectiveness
 - Quality management systems
 - Regulatory impact analyses



INCREASE RELEVANCE IN REGULATION

1. Continuing systematic review of existing rules and regulations to ensure relevance and effectiveness

- Quality management systems
- Regulatory impact analyses

 2. Going beyond regulating for minimum standards and safety towards regulating for quality
The beyond apply frameworks for rational decision-

Develop and apply frameworks for rational decision making



INCREASE RELEVANCE IN REGULATION


 Continuing systematic review of existing rules and regulations to ensure relevance and effectiveness

- Quality management systems
- Regulatory impact analyses

 Going beyond regulating for minimum standards and safety towards regulating for quality
Develop and apply frameworks for rational decisionmaking

 Ensuring well-informed stakeholder population
Effective communication and engagement of stakeholders

MEDICINES REGULATION - PROTECTING PUBLIC



Promoting the Quality of Medicines | ©2016. ALL RIGHTS RESERVED.

Source: The World Bank, 2005. Good Practices for Regulatory Inspections: Guidelines for Reformers



Areas where regulators do not have:


- Expertise and skills
- Adequate data
- Intention to regulate directly due to, in part, above
- Clear regulatory mandate
- Adequate law and regulations to back them up

Regulators would then face challenges in defining regulatory space and balance:

- What are regulators' obligations and at what level to regulate?
- What are stakeholders' expectations?
- How to communicate to align obligation with expectations?

At any rate, public may still hold regulator responsible and accountable for if severe adverse reactions or events occur.

MEDICINES REGULATORY TOOLKIT



Promoting the Quality of Medicines ©2016. ALL RIGHTS RESERVED



Protect public health and safety

 Allow timely access to QSE as well as innovative therapies and products



• Be sensitive to

• Apply user-friendly


concerns

policies

Promoting the Quality of Medicines | ©2016. ALL RIGHTS RESERVED.



ADOPTING RISK-BASED REGULATION



Promoting the Quality of Medicines ©2016. ALL RIGHTS RESERVED.




Regional and international collaboration in drug regulation has led to the creation of regional and international instruments to facilitate control and harmonization of technical and regulatory requirements. Examples are:

- 1. European Medicines Evaluation Agency (EMEA)
- The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) to achieve greater harmonization to ensure that safe, effective, and high quality medicines
- 3. The Association of South-East Asian Nations (ASEAN) on application for registration (ACTD), GMP inspection, and BA/BE protocol
- 4. PIC/S on GMP inspectorate standards
- 5. International Conference of Drug Regulatory Authorities (ICDRA)
- New Partnership for Africa's Development (NEPAD) thru East African Community Medicines Regulatory Harmonization (EAC/MRH) program, African Drug Regulatory Authority Network (AFDRAN)




Challenges in regulatory measures for quality assured medicines: registration, licensing & inspection, and testing – what should be the top priority?



Promoting the Quality of Medicines ©2016. ALL RIGHTS RESERVED.


PCM Challenges in key regulation areas: workload of inspectors



Distribution channels — includes all types of drug outlet.

** For Australia, no data are available about the number of distribution-channel inspectors.


POM Challenges in key regulation areas: workload of product evaluators





Exercise – 5 minutes

Based on your experience, please name 4-5 factors that contribute to the effectiveness of medicines regulation (in your country):



WHAT FACTORS CONTRIBUTING TO EFFECTIVE MEDICINES REGULATION IN GENERAL CONTEXT?

- 1. Political will and commitment to regulation
- 2. Adequate supply of medicines at affordable prices
- 3. Strong public support for drug regulation and regulatory system
- 4. Effective cooperation between the national medicines regulatory authority (MRA) and other government law enforcement agencies (e.g. customs and police)
- 5. Sufficient qualified and experienced pharmaceutical and other health professionals
- 6. Political environment favoring independent technical decisionmaking
- 7. Effective legislation to support and empower MRA to carry out its key functions and responsibilities




WHAT FACTORS CONTRIBUTING TO EFFECTIVE REGULATION WITHIN AN MRA?

- 1. Clear mission
- 2. Adequate medicines legislation and regulation
- 3. Appropriate organizational structure and facilities
- 4. Clearly defined roles and responsibilities
- 5. Adequate and sustainable financial resources, including resources to retain and develop staff
- 6. Appropriate tools, such as standards, guidelines and procedures
- 7. Strong cooperation and collaboration between MRAs and other stakeholders
- 8. Accountability and transparency
- 9. Good management system




Would financial imbalance between regulator and his/her private counterpart affect the effectiveness of medicines regulation?





If a medicines regulation is to bring about the ultimate outcome of protecting public health and safety with quality assured, safe, and efficacious medications, certain structural, process arrangements must be securely in place.



Promoting the Quality of Medicines | ©2016. ALL RIGHTS RESERVED.



The author/presenter wishes to acknowledge the following institutions, organizations and programs for their support and cooperation:

- The United States Agency for International Development
- The United States Pharmacopeial Convention Promoting the Quality of Medicines Program
- The Boston University School of Public Health
- University of Oxford



Thank You

Inquiries? Please contact: Souly Phanouvong at <u>sxp@usp.org</u>



This document is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of the Promoting the Quality of Medicines program and do not necessarily reflect the views of USAID or the United States Government.

